An Expert View from David Bleakman, president, Drug Discovery and Development at PsychoGenics.
For decades, the development of the next generations of drugs for neuropsychiatric symptoms has been one of the greatest challenges in neuroscience drug discovery.
In particular, the need to improve upon standard of care with respect to side effects or efficacy in treatment-resistant patient populations. We have seen a lot of novel molecular targets implicated and drugs clinically tested targeting depression, schizophrenia and neurodegenerative disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze